<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880968</url>
  </required_header>
  <id_info>
    <org_study_id>2012-13</org_study_id>
    <nct_id>NCT03880968</nct_id>
  </id_info>
  <brief_title>Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis</brief_title>
  <acronym>T2TEAS</acronym>
  <official_title>Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jiaxing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaoxing Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaoxing People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the disease activity guided tapering and discontinuation strategies of etanercept
      (ETN) in patients with ankylosing spondylitis (AS) in 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2012</start_date>
  <completion_date type="Actual">September 30, 2014</completion_date>
  <primary_completion_date type="Actual">September 30, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative flare rates at week 48 with different tapering or discontinuation strategies</measure>
    <time_frame>48 weeks</time_frame>
    <description>Cumulative flare rates at week 48 with different tapering or discontinuation strategies</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Spondylitis, Ankylosing</condition>
  <arm_group>
    <arm_group_label>inactive - half dosage tapering</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS&lt;1.3, group A) at week 12 and assigned to sequential tapering group (A1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inactive - discontinuation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS&lt;1.3, group A) at week 12 and then assigned to discontinuation group (A2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low disease activity - half dosage tapering</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS&lt;2.1, group B) and designated to sequential tapering group (B1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low disease activity - full dosage tapering</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS&lt;2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low disease activity - discontinuation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS&lt;2.1, group B) and designated to discontinuation group (B3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapering or discontinuation of etanercept</intervention_name>
    <description>Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS&lt;1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS&lt;2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).</description>
    <arm_group_label>inactive - discontinuation</arm_group_label>
    <arm_group_label>inactive - half dosage tapering</arm_group_label>
    <arm_group_label>low disease activity - discontinuation</arm_group_label>
    <arm_group_label>low disease activity - full dosage tapering</arm_group_label>
    <arm_group_label>low disease activity - half dosage tapering</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 18 years old and 65 years old with AS, according to 1984-revised New York
             classification criteria.

          -  an active disease of ASDAS with C reactive protein (ASDAS-CRP) ≥2.1.

          -  a disease duration of 6 months to 30 years.

          -  no exposure to biologics in recent 6 months before recruitment. Concomitant
             medications with NSAIDs, conventional disease modifying anti-rheumatic drugs
             (cDMARDs), or prednisone or a prednisone equivalent (≤10mg/day), were allowed to
             continue if they were maintained at a stable dose for 4 weeks or more from baseline.

        Exclusion Criteria:

          -  late-stage patients with spinal fusion.

          -  patients with severe cardiac, hepatic, renal, hematologic or endocrine diseases.

          -  patients with a history of multiple sclerosis, current or past malignancy.

          -  patients who were pregnant, or planning to become pregnant, or breastfeeding.

          -  patients with active or recurrent infections, or those who required oral antibiotics 2
             weeks or intravenous antibiotics 4 weeks before screening.

          -  patients with current or past or potential tuberculosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huaxiang Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>wuhx8855@sina.com</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 17, 2019</last_update_submitted>
  <last_update_submitted_qc>March 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

